Atezolizumab bulk supplier for pharma manufacturers

Atezolizumab 1200 mg/20 mL Suppliers & Bulk Manufacturers

Available Forms: Intravenous infusion

Available Strengths: 1200 mg/20 mL

Reference Brands: Tecentriq® (EU & US)

Atezolizumab (Tecentriq®) is a PD-L1 checkpoint inhibitor used in urothelial carcinoma, NSCLC, and triple-negative breast cancer. Available as sterile IV infusion vials (1200 mg/20 mL), manufactured under EU-GMP and USFDA standards. Ideal for B2B supply, hospital tenders, and licensing.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

Product Description:

Atezolizumab (Tecentriq®) is a PD-L1 immune checkpoint inhibitor indicated for urothelial carcinoma, NSCLC, and triple-negative breast cancer. Provided as sterile intravenous infusion vials (1200 mg/20 mL), Atezolizumab is produced under EU-GMP and USFDA standards. Offered for B2B supply, contract manufacturing, and licensing, it supports hospital tenders and oncology distributors with full regulatory documentation. This monoclonal antibody restores anti-tumor immunity by blocking PD-L1, making it a vital immuno-oncology therapy in US and European cancer treatment portfolios.

Atezolizumab — third party manufacturing & bulk supply

Atezolizumab 1200 mg/20 mL is available through PharmaTradz for wholesale and bulk supply as well as on a third party (contract) manufacturing basis. Buyers sourcing this product generally take one of three routes:

Wholesale / bulk supply Stock or scheduled supply from an existing manufacturer. The fastest route where the product is already registered in your market.

Third party manufacturing Manufactured to your specification and packed under your own brand and label — suits distributors and brand owners building a portfolio in their market.

Dossier licensing Where a CTD, EU-CTD or ACTD dossier exists it can often be licensed for filing in your name, compressing market entry from years to months.

Indicative minimum order quantity

Atezolizumab is supplied as Intravenous infusion — an injectable dosage form, so the indicative MOQ is 50,000 units. Actual MOQ is confirmed by the allocated manufacturer against your pack presentation and destination market. See full supply terms for dossier formats, market availability and shelf life.

Manufacturers of Atezolizumab listed on PharmaTradz hold site-level approvals across WHO-GMP, EU-GMP, USFDA, ANVISA and TGA, verified at onboarding.

Request a quote for Atezolizumab →

Back to Listing

Frequently Asked Questions

Atezolizumab is used to treat several types of cancer, including non-small cell lung cancer, small cell lung cancer, hepatocellular carcinoma, triple-negative breast cancer, and urothelial carcinoma. It works by blocking the PD-L1 protein on tumor cells, helping the immune system detect and destroy cancer cells more effectively.

Atezolizumab is a humanized monoclonal antibody created using recombinant DNA technology. It is produced from genetically engineered Chinese hamster ovary (CHO) cells that express an antibody specifically targeting PD-L1, a protein found on tumor and immune cells.

The trade name of Atezolizumab is Tecentriq.

Atezolizumab is developed and manufactured by Genentech, Inc., which is a member of the Roche Group, a global leader in cancer immunotherapy.

The generic name of the product is Atezolizumab.

The brand name of the product is Tecentriq.

Atezolizumab (Tecentriq) is manufactured by Genentech, Inc. in the United States, and additional manufacturing and packaging for international supply are handled at Roche production facilities in Europe and other regions.